Skip to content

Author

Yu-Yang Cui

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-World Safety Profile of Mirvetuximab Soravtansine: A Population-Based Pharmacovigilance Study Leveraging FAERS and EudraVigilance Databases.

PURPOSE Mirvetuximab soravtansine (MIRV) is the first FDA-approved antibody-drug conjugate targeting folate receptor-α (FRα)-positive platinum-resistant ovarian cancer. Despite its clinical adoption, comprehensive post-marketing real-world evidence regarding its safety profile remains limited. This study aimed to syste...

Zhi-Wei Cui, Ping Song, De Xie et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.